| 創建日期 | 上櫃日期 | 董事長 | 總經理 |
|---|---|---|---|
| 101/10/12 | 107/04/17 | 張銘政 | 陳燦堅 |
| EPS | 本益比 | 股價淨值比 | 現金殖利率 |
| -0.96(Q2) | 0 | 5.26 | 0% |
| 實收資本額 | 已發行普通股 | ||
| 3,283,568,000 | 328,356,800 | ||
| 主要經營業務 | |||
| 疫苗研發製造生物製劑研發製造 | |||
| 公司網址 | |||
| medigenvac.com | |||
高端疫苗(6547) 月營收報表
| 年度/月份 | 營業收入（單位：千元） | 累計營業收入（單位：千元） | |||||
|---|---|---|---|---|---|---|---|
| 單月營收 | 去年同月營收 | 單月月增率 | 單月年增率 | 累計營收 | 去年累計營收 | 累積年增率 | |
| 2023/08 | 101,626 | 419 | 0% | 24154.4% | 101,626 | 340,178 | -70.1% |
| 2023/07 | 0 | 542 | 0% | -100% | 0 | 339,759 | -100% |
| 2023/06 | 0 | 1,836 | 0% | -100% | 0 | 339,217 | -100% |
| 2023/05 | 0 | 2,319 | 0% | -100% | 0 | 337,381 | -100% |
| 2023/04 | 0 | 8,428 | 0% | -100% | 0 | 335,062 | -100% |
| 2023/03 | 0 | 87,817 | 0% | -100% | 0 | 326,634 | -100% |
| 2023/02 | 0 | 3,033 | 0% | -100% | 0 | 238,817 | -100% |
| 2023/01 | 0 | 235,784 | -100% | -100% | 0 | 235,784 | -100% |
| 2022/12 | 5,794 | 286,249 | -35.7% | -98% | 365,042 | 3,280,994 | -88.9% |
| 2022/11 | 9,009 | 1,157,186 | 0.9% | -99.2% | 359,249 | 2,994,745 | -88% |
| 2022/10 | 8,928 | 586,585 | 688% | -98.5% | 350,239 | 1,837,559 | -80.9% |
| 2022/09 | 1,133 | 518,897 | 170.4% | -99.8% | 341,311 | 1,250,974 | -72.7% |
| 2022/08 | 419 | 727,544 | -22.7% | -99.9% | 340,178 | 732,077 | -53.5% |
| 2022/07 | 542 | 457 | -70.5% | 18.6% | 339,759 | 4,533 | 7395.2% |
| 2022/06 | 1,836 | 933 | -20.8% | 96.8% | 339,217 | 4,076 | 8222.3% |
| 2022/05 | 2,319 | 0 | -72.5% | 0% | 337,381 | 3,143 | 10634.4% |
| 2022/04 | 8,428 | 0 | -90.4% | 0% | 335,062 | 3,143 | 10560.6% |
| 2022/03 | 87,817 | 1,143 | 2795.4% | 7583% | 326,634 | 3,143 | 10292.4% |
| 2022/02 | 3,033 | 0 | -98.7% | 0% | 238,817 | 2,000 | 11840.8% |
| 2022/01 | 235,784 | 2,000 | -17.6% | 11689.2% | 235,784 | 2,000 | 11689.2% |
| 2021/12 | 286,249 | 3,353 | -75.3% | 8437.1% | 3,280,994 | 11,506 | 28415.5% |
| 2021/11 | 1,157,186 | 2,236 | 97.3% | 51652.5% | 2,994,745 | 8,153 | 36631.8% |
| 2021/10 | 586,585 | 1,337 | 13% | 43773.2% | 1,837,559 | 5,917 | 30955.6% |
| 2021/09 | 518,897 | 1,746 | -28.7% | 29619.2% | 1,250,974 | 4,580 | 27213.8% |
| 2021/08 | 727,544 | 568 | 159100% | 127988.7% | 732,077 | 2,834 | 25731.9% |
| 2021/07 | 457 | 635 | -51% | -28% | 4,533 | 2,266 | 100% |
| 2021/06 | 933 | 968 | 0% | -3.6% | 4,076 | 1,631 | 149.9% |
| 2021/05 | 0 | 183 | 0% | -100% | 3,143 | 663 | 374% |
| 2021/04 | 0 | 0 | -100% | 0% | 3,143 | 480 | 554.8% |
| 2021/03 | 1,143 | 0 | 0% | 0% | 3,143 | 480 | 554.8% |
| 2021/02 | 0 | 0 | -100% | 0% | 2,000 | 480 | 316.7% |
| 2021/01 | 2,000 | 480 | -40.3% | 316.7% | 2,000 | 480 | 316.7% |
| 2020/12 | 3,353 | 0 | 50% | 0% | 11,506 | 1,120 | 927.3% |
| 2020/11 | 2,236 | 0 | 67.2% | 0% | 8,153 | 1,120 | 627.9% |
| 2020/10 | 1,337 | 480 | -23.4% | 178.5% | 5,917 | 1,120 | 428.3% |
| 2020/09 | 1,746 | 0 | 207.4% | 0% | 4,580 | 640 | 615.6% |
評論0